(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

COMBINAÇÃO DO INIBIDOR HDAC E ANTICORPIDO ANTI-PD-L1 PARA O TRATAMENTO DO CÂNCER

ArquivadaInvention PatentPCT · US2016039906

Application data

Number

112017028287

Type

Invention Patent

Filing

06/28/2016

Publication

09/04/2018

PCT

US2016039906

Progress at the INPI

  1. Filing06/28/16
  2. Publication09/04/18
  3. Abandoned
  4. Allowance
  5. Grant
  6. In force

The application was abandoned: examination was not requested within the 36 months following the 06/28/2016 filing, the deadline set by art. 33 of the Brazilian IP Act. The technology is in the public domain in Brazil.

Talk to a specialist

Latest action published by the INPI: 10/01/2019. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

SYNDAX PHARMACEUTICALS, INC.

US

See this company's full portfolio

Inventors

P. O. (pessoa física)

US

R. G. (pessoa física)

US

Technical data

Priority claims

US

62/186,237 · 06/29/2015

Abstract

A presente invenção refere-se aos métodos descritos aqui para o tratamento de câncer de mama em um indivíduo. Em particular, são fornecidos métodos para o tratamento do câncer de mama triplo negativo metastático com uma combinação de entinostat e um anticorpo anti-PD-L1, como o MPDL3280A.

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Arquivamento definitivo - Art. 33 da LPI

#11.1.1

10/01/2019

RPI 2543

Arquivamento - Art. 33 da LPI

#11.1

07/16/2019

RPI 2532

Notificação de entrada na fase nacional - PCT

#1.3

09/04/2018

RPI 2487

Alteração de dados cadastrais

#1.1

04/03/2018

RPI 2465

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.